Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hip implant performance under review in completed study

NCT ID NCT05606120

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at 54 people who had a hip replacement with a specific part called the CL TRAUMA cemented stem. The goal was to see if the part was safe and worked well. Researchers measured how well patients could move and if they had pain using a standard hip score.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

54 people

The number who actually took part.

Started

Dec 2022

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The eligible study population is represented by the entire population that underwent a hip replacement with CL TRAUMA femoral stem from 2017 to 2023.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female; 2. Age \> 18 years old; 3. All patients must give written informed consent approved by the study site's Institutional Review Board (IRB)/Ethical Committee (EC); 4. Adult patients in whom a decision has already been made to perform a partial or total hip arthroplasty with CL TRAUMA femoral stem as per indication for use. The decision to implant CL TRAUMA must be taken prior to, and independently from the decision to enroll the patient. This decision should be made in accordance with routine clinical practice at the study site concerned; 5. Patients suffering from: non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and dysplasia; or suffering from rheumatoid arthritis; or patients requiring treatment of femoral head and neck fractures; 6. Patients able to comply with the protocol. Exclusion Criteria: 1. Adult patients with any CL TRAUMA femoral stem contraindication for use as reported in the current local Instruction for use; 2. Patients with active or any suspected infection (on the affected hip or systemic); 3. Patients suffering from acute or chronic osteomyelitis; 4. Patients with confirmed nerve or muscle lesion compromising hip joint function; 5. Patients with vascular or nerve diseases affecting the concerned limb; 6. Patients with poor bone stock (such as osteoporosis or extended previous revision surgery) compromising the stability of the implant; 7. Patients with metabolic disorders which may impair fixation and stability of the implant; 8. Any concomitant disease and dependence that might affect the implanted prosthesis; 9. Patients with known incompatibility or allergy to the product materials, and/or metal hypersensitivity to implant materials; 10. Patients currently participating in any other surgical intervention studies or pain management studies; 11. Female patients who are pregnant, nursing or planning a pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azienda Ospedale Università di Padova

    Padova, Padova, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.